Arecor Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
Arecor Therapeutics has a total shareholder equity of £5.1M and total debt of £0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are £10.4M and £5.3M respectively.
Key information
0%
Debt to equity ratio
UK£0
Debt
| Interest coverage ratio | n/a |
| Cash | UK£2.55m |
| Equity | UK£5.08m |
| Total liabilities | UK£5.29m |
| Total assets | UK£10.37m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 6UI's short term assets (£6.4M) exceed its short term liabilities (£4.7M).
Long Term Liabilities: 6UI's short term assets (£6.4M) exceed its long term liabilities (£625.0K).
Debt to Equity History and Analysis
Debt Level: 6UI is debt free.
Reducing Debt: 6UI had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 6UI has sufficient cash runway for 5 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: 6UI is forecast to have sufficient cash runway for 11 months based on free cash flow estimates, but has since raised additional capital.